Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
TO THE EDITOR
Chronic myeloid leukaemia (CML) is characterised by the presence of a t(9;22)(q34;q11) reciprocal translocation in over 90% of cases, leading to a Bcr-Abl fusion protein whose increased tyrosine kinase activity is essential for the pathogenesis of the disease. In most CML patients, the breakpoint on the BCR gene occurs in the major breakpoint cluster region (M-bcr), leading to e13a2 and/or e14a2 fusion transcripts and a Bcr-Abl protein of 210 kDa. Breakpoints outside M-bcr occur infrequently in CML, in either m-bcr, producing e1a2 fusion transcripts and a p190 KDa fusion protein, or in the m-bcr region, generating long e19a2 mRNA molecules and the larger p230 BcrÀAbl protein. Other atypical BCR-ABL transcripts with fusions such as e13a3, e14a3 or e6a2 are very rare and have been only occasionally described. [1] [2] [3] We report here a second case of a Philadelphia(Ph)-positive CML patient with an e6a2 BCR-ABL fusion transcript.
A 65-year-old male patient who was previously fit presented in November 2002 with symptoms of anaemia, weight loss and night sweats. At that time, gingival hypertrophy was noted, but hepatosplenomegaly and lymphadenopathy were absent. His peripheral blood showed a haemoglobin concentration of 68 g/l and a platelet count of 88 Â 10 9 /l. The white blood cell (WBC) count was 157 Â 10 9 /l, with 63% myeloblasts, 5% promyelocytes, 3% metamyelocytes, 7% myelocytes, 7% neutrophils, 2% eosinophils, 11% basophils and 2% lymphocytes. The bone marrow morphology was consistent with myeloid blast crisis of CML. Standard cytogenetics by Giemsa banding revealed a typical t(9;22)(q34;q11) translocation in all eight metaphases examined, with no additional chromosomal abnormalities. Screening by fluorescent in situ hybridisation for BCR-ABL fusion was positive in 98 of 100 interphases. RNA was extracted using the RNeasyt kit (Qiagen, Crawley, UK), and cDNA was synthesised using Superscript II RNase Hreverse transcriptase (Invitrogen, Paisley, UK) and random hexamer oligonucleotides. An initial multiplex RT-PCR for BCR-ABL using standard protocols 4 proved to be negative for BCR-ABL amplification (Figure 1a) . Therefore, amplification reactions specific for p210, p190 and p230 BCR-ABL fusion transcripts were performed. Using primers BCR1 þ (5 0 -GAACTCGCAACAGTCCTTCGAC-3 0 ) and Abl3-(5 0 -GGTAC CAGGAGTGTTTCTCCAGACTG-3 0 ), the presence of a PCR product larger than the e1a2 but smaller than an e13a2 transcript was observed (Figure 1b) . This fragment was gel purified and upon automated sequencing was identified as an e6a2 fusion transcript. RT-PCR reactions with the same reverse primer on ABL and forward primers on BCR exons 9 (for p210-type transcripts) or 18 (for p230 type) proved to be negative, whereas the normal copies of both the ABL and BCR genes could be amplified from the patient's cDNA (data not shown).
The patient was treated with blood product support, hydroxyurea and subsequently imatinib mesylate, leading to a reduction in the WBC count to 1.3 Â 10 9 /l (with 60% neutrophils) after 30 days of treatment. However, he subsequently developed pneumonia, and died 42 days after initial diagnosis.
In contrast to the patients previously studied by multiplex RT-PCR, we were unable to readily detect the e6a2 fusion transcript by this method. Repeated multiplex RT-PCR reactions using different preparations of good-quality cDNA only proved to be positive for BCR-ABL in one out of three reactions; even in this instance, the intensity of the visualised BCR-ABL band was too low to be conclusive. Thus, a specific PCR using primers on BCR exon 1 and ABL exon 3 was required for the reliable detection of a BCR-ABL fusion transcript. We therefore recommend that cDNA from any patient with the clinical and cytogenetic pictures of CML and apparently negative results for BCR-ABL amplification by multiplex PCR be examined by RT-PCR with specific primers for p210, p190 and p230 gene configurations in order not to miss the presence of atypical BCR-ABL junctions. In the case of an e6a2 message as described here, the resulting PCR product from amplification with primers designed for detection of p190 transcripts is rather long (B1 kb). As we show in Figure 1b , even BCR-ABL fusion transcripts up to 1.9 kb can be amplified if the cDNA is of very high quality, but this cannot always be achieved from primary material sent for diagnostic purposes. Therefore, an additional PCR reaction using a forward primer in BCR-ABL exon 5 or 6 should be included if despite clinical and cytogenetic evidence of a CML no fusion transcript can be identified using the primer combinations mentioned above.
Since very few patients have been reported with unusual BCR-ABL fusion transcripts, predictions concerning their specific prognosis cannot yet be made. Of the three known patients with e6a2 transcripts, one (this case report) presented in blast crisis, and a second one rapidly accelerated with extramedullary manifestations of his disease. 2 Whether this fusion transcript leads to a more aggressive type of disease is still not known at present. The e1a2 BCR-ABL gene derived from a m-bcr breakpoint is more often associated with Ph chromosomepositive acute lymphoblastic leukaemia than with CML. In the very rare cases of p190 (e1a2) CML, where the fusion protein differs from the traditional p210 by the lack of the central guanine exchange factor (GEF)/dbl-like domain of Bcr, the disease tends to have a significant monocytic component and a conspicuous absence of splenomegaly, but is otherwise similar to classical CML. 5, 6 In patients with e6a2 transcripts, the breakpoint on BCR probably occurs in the middle of the GEF/ dbl-like domain, which is therefore only partially contained in the resulting Bcr-Abl fusion protein. Since this domain mediates interaction with several G proteins involved in cell growth and signalling, 7 it is possible that its truncation has transforming properties that can enhance the oncogenic potential of the p190 Bcr-Abl fusion. In order to gain more insight into this, clinical data on such patients should be carefully recorded aiming at further characterising the course of the disease and improving the outcome by individualising therapeutic strategies. 
